ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1].
Molecular Weight:
506.33
Purity:
99.93
CAS Number:
[459789-75-4]
Formula:
C27H17Cl2NO5
Target:
Tim3
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
